Data on new Novo Nordisk obesity drug disappoints in trial, shares drop
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.
New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.
It's not too often that pharmaceutical drugs become household names, but that's happening with medicines in the weight loss market. Brands such as Wegovy and Zepbound -- the leading anti-obesity ...
Stanford Medicine researchers have identified a naturally occurring molecule that mimics the appetite-suppressing effects of ...
Some commercially insured patients stand to save $150 per month on Wegovy, a popular obesity medication. Patients on Medicare ...
Researchers linked higher weight loss after initiating antiobesity meds to lower risk for revision of hip and knee replacement.
The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...
A new study breaks down exactly how to stop eating ultra-processed foods in eight weeks. Here's what it found and what ...
Fenugreek seeds can help you a lot in reducing obesity and belly fat. Fenugreek seeds have anti inflammatory properties that can help improve overall health. They speed up metabolism and reduce belly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback